Avalon Pharmaceuticals Inc - Amended Current report filing (8-K/A)
24 Julho 2008 - 1:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
March 14, 2008
|
AVALON PHARMACEUTICALS, INC.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-32629
|
52-2209310
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
20358 Seneca Meadows Parkway, Germantown, Maryland
|
|
20876
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
301-556-9900
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) This amendment to the Current Report on Form 8-K of Avalon Pharmaceuticals, Inc. (the "Company"), dated March 14, 2008 and filed on March 17, 2008 is being filed to report that Dr. Philip Frost, previously announced as being appointed to the Company's board of directors, was appointed on July 23, 2008 as a member of the Company's Nominating and Corporate Governance Committee.
Except as noted herein, the Company's Current Report on Form 8-K remains as originally filed with the Securities and Exchange Commission on March 17, 2008.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
AVALON PHARMACEUTICALS, INC.
|
|
|
|
|
|
July 24, 2008
|
|
By:
|
|
/s/ Thomas G. David, Esq.
|
|
|
|
|
|
|
|
|
|
Name: Thomas G. David, Esq.
|
|
|
|
|
Title: General Counsel and Senior VP of Operations
|
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Avalon Pharmaceuticals (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Avalon Pharmaceuticals Inc